Omeros Secures FDA Approval for YARTEMLEA, Boosts Liquidity with $240M Zaltenibart Deal & New Buyback Program

summarizeSummary

Omeros Corporation reported a significantly reduced net loss for 2025, driven by the FDA approval of its first-in-class drug YARTEMLEA and a substantial $240 million upfront payment from Novo Nordisk for global rights to zaltenibart, alongside a new $100 million share repurchase program.

check_boxKey Events

• FDA Approval of YARTEMLEA

  Received FDA approval on December 23, 2025, for YARTEMLEA (narsoplimab-wuug) as the first and only approved therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Commercial sales began in January 2026.

• Strategic Partnership with Novo Nordisk

  Completed the sale of exclusive global rights to zaltenibart (MASP-3 inhibitor) to Novo Nordisk for an upfront cash payment of $240.0 million, with eligibility for up to $510.0 million in development/approval milestones and $1.3 billion in sales milestones, plus tiered royalties.

• Improved Financial Performance & Liquidity

  Reported a net loss of $3.350 million for 2025, a significant reduction from $156.815 million in 2024, and ended the year with $171.8 million in cash, cash equivalents, and short-term investments, expecting to fund operations for over 12 months.

• Debt Reduction

  Decreased aggregate principal debt by $77.1 million to $87.9 million as of December 31, 2025, with the remaining $17.1 million of 2026 Notes repaid in February 2026.

auto_awesomeAnalysis

This 10-K filing reveals a pivotal year for Omeros, marked by two highly significant positive developments. The FDA approval of YARTEMLEA (narsoplimab-wuug) as the first and only approved therapy for TA-TMA is a transformational event, transitioning the company to a commercial stage with sales commencing in January 2026. Concurrently, the strategic partnership with Novo Nordisk, involving the sale of global rights to zaltenibart for a $240 million upfront payment and potential future milestones up to $1.8 billion, substantially strengthens Omeros's financial position and validates its MASP-3 program. These events collectively led to a dramatic reduction in net loss and improved liquidity, with the company now expecting to fund operations for over 12 months. The approval of a new $100 million share repurchase program further signals management's confidence in the company's future prospects and capital management strategy, even as it continues to utilize ATM and direct offerings for capital.